About HCL Capital
HCL Capital is a venture capital firm located in Hong Kong, China. As of Jun 2022, HCL Capital has invested in 14 companies. It primarily invests in Seed round in China based startups. Its investments are spread across a wide range of sectors from Life Sciences to HealthTech and High Tech. Most recently it participated in the $***** Seed round of Flow Overall, HCL Capital portfolio has seen 5 IPOs including key companies like ClearPoint Neuro, Atea and Hastings Technology Metals. A lot of funds co-invest with HCL Capital, with names like Multiples Alternate Asset Management sharing a substantial percentage of its portfolio.Key Metrics
Portfolio Count
Portfolio Sectors
Portfolio Locations
Rounds of Entry
PE & Seed
Portfolio Soonicorns
HCL Capital's List of Top Investments
HCL Capital has a portfolio of 14 companies. Their most notable investments include ClearPoint Neuro and Atea.Their portfolio spans across United States, Australia, India and 2 more locations. They have invested in Life Sciences, HealthTech, High Tech and 7 other sectors, across stages such as PE, Seed stages. Here is the list of top investments by HCL Capital:
Developer of MRI-guided stereotactic system for neurological interventions. It specializes in precise navigation systems for brain and spine procedures, enabling device, cell, and gene therapies with real-time imaging and minimally invasive techniques.
Key facts about ClearPoint Neuro
- Founded Year: 1998
- Location: Irvine (United States)
- Annual Revenue: $10M - $50M as on Dec 31, 2025
- Stage: Public
- Total Funding till date: $33.7M
- Employee Count: 158 as on Aug 31, 2026
- Investors: Oberland Capital, Collage Venture Partners and 5 Others
- Latest Funding Round: Post IPO, May 19, 2025, $*****
- Highlight: Public
_1579497693661.png?format=webp&height=120&width=120){kind=logo}
2. Atea
Developer of therapeutics for viral diseases. It helps users in the treatment of infections caused by RNA and DNA viruses. It also gives solutions for various diseases like Hepatitis C, Dengue, Respiratory Syncytial Virus (RSV), Hepatitis B, and many more.
Key facts about Atea
- Founded Year: 2014
- Location: Boston (United States)
- Stage: Public
- Total Funding till date: $293M
- Employee Count: 58 as on Aug 31, 2026
- Investors: HTIF, Bain Capital Life Sciences and 18 Others
- Latest Funding Round: Post IPO, Jun 13, 2023, $*****
- Highlight: Public
3. Alzheon
Developer of disease-modifying treatments for Alzheimer's disease and other neurodegenerative disorders. The company's product line include ALZ-801 (prodrug of active compound tramiprosate), is a first-in-class, oral inhibitor of amyloid aggregation and neurotoxicity hallmarks of Alzheimer’s disease.
Key facts about Alzheon
- Founded Year: 2013
- Location: Framingham (United States)
- Valuation: $*****
- Stage: Series E
- Total Funding till date: $274M
- Employee Count: 30 as on Sep 30, 2026
- Investors: Collage Venture Partners, Ally Bridge Group and 4 Others
- Latest Funding Round: Series E, Aug 26, 2026, $*****
- Highlight: Editors' Pick
BDR Pharmaceuticals develops and manufactures API. The company also offer new delivery systems and development of new generics. The products are of various therapeutic categories including oncology, critical care, gynecology, respiratory, antidiabetics, neurology, and others. The company has manufacturing facilities certified by WHO-GMP.
Key facts about BDR Pharmaceuticals
- Founded Year: 2003
- Location: Mumbai (India)
- Annual Revenue: ₹1,000+ Cr as on Mar 31, 2025
- Valuation: $*****
- Stage: Late Stage
- Total Funding till date: $94.9M
- Employee Count: 1,006 as on Sep 30, 2026
- Investors: Multiples Alternate Asset Management, HCL Capital and 13 Others
- Latest Funding Round: PE, Jan 24, 2022, $*****
Provider of research based assessment and talent‑identification tools for schools and educators. They offer assessments designed to identify learning gaps and measure student understanding. The company provides resources for educators and tools to support personalized learning experiences. Their offerings include assessments for various subjects and skill-based diagnostic testing.
Key facts about Educational Initiatives
- Founded Year: 2001
- Location: Bengaluru (India)
- Annual Revenue: ₹100 - ₹500 Cr as on Mar 31, 2026
- Valuation: $*****
- Stage: Series A
- Total Funding till date: $30.7M
- Employee Count: 404 as on May 01, 2026
- Investors: Dvara Holdings, Footprint Ventures and 22 Others
- Latest Funding Round: Grant (prize money), 2021, $*****
- Highlight: Editors' Pick
HCL Capital's Year-on-Year Investment Trends
Its most recent first time investment was in Flow.HCL Capital's Investments by Stage
HCL Capital has made 1 investment in PE stage with an average round size of $94.9M and 1 investment in Seed stage with an average round size of $1M.HCL Capital's Investments by Sector
HCL Capital has a diverse portfolio, with companies operating in the Consumer, Life Sciences and Travel and Hospitality Tech. Notably, it has invested in 10 Enterprise (B2B) companies, 10 Tech companies, 4 Software companies and at least 3 companies focusing on Consumer (B2C).Sector | No. of Investments |
|---|---|
Consumer | 1 |
Life Sciences | 1 |
Travel and Hospitality Tech | 1 |
Note: We have considered here, only first round of investments
HCL Capital's Investments by Geography
HCL Capital has made most investments in China (1), followed by India where it has made 1 investment.HCL Capital's recent investments
HCL Capital has not made any investment in 2026 so far.Here are the most recent investments by HCL Capital:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Jun 13, 2022 | China | Seed | 8504 | [+2] | |
Jan 24, 2022 | India | PE | 9864 |
IPOs and Publicly Listed companies in HCL Capital's Portfolio
5 of HCL Capital's portfolio companies have become public. Atea got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ), in Oct 2020 and Atreca got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ) at marketcap of $455M.Here are HCL Capital's portfolio companies that went public:
Company | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Oct 30, 2020 | - | - | 9313 | |
Jun 20, 2019 | - | - | 5212 | |
Aug 15, 2016 | - | - | 2302 | |
Feb 20, 2008 | - | - | 9453 | |
Nov 05, 2003 | - | - | 3767 |
_1579497693661.png?devicePixelRatio=2&height=20&width=20){kind=logo}
Co-investors of HCL Capital
Over the past 4 years, 12 investors have co-invested in HCL Capital's portfolio companies. This includes funds and angels.
- Top Co-investors of HCL Capital: 12 investors entered a company along with HCL Capital. These include investors like Multiples Alternate Asset Management (1 company).
Recent News related to HCL Capital
•
Hong Kong Tech Startup, Flow, Raises Over US$1 million Series Pre-A Funding to Accelerate Expansion in SoutheastUserwalls•Jun 13, 2022•Flow, HCL Capital
•
YC alum Dropee, a Malaysia B2B wholesale platform, lands $7M Series ATechCrunch+•Jan 20, 2022•Borong, HCL Technologies, Resolution Foundation, Lan Kwai Fong Group and 5 others
